Theodore R Johnson et al.
Xenobiotica; the fate of foreign compounds in biological systems, 45(1), 45-59 (2014-07-19)
1. Crizotinib (XALKORI®), an oral inhibitor of anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition factor kinase (c-Met), is currently approved for the treatment of patients with non-small cell lung cancer that is ALK-positive. 2. The metabolism, excretion and pharmacokinetics of